1. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
Clin Endocrinol (Oxf). 2004 Jun;60(6):694-8.

2. Role of flowmetric analysis and of color-Doppler ultrasonography with contrast media in the different phases and follow-up of Graves' disease
Radiol Med (Torino). 2001 Oct;102(4):233-7. Italian.

3. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
J Clin Endocrinol Metab. 1998 Apr;83(4):1222-5.

4. Autoimmune Addison's disease. Current knowledge and prospects
Minerva Endocrinol. 1996 Mar;21(1):1-6. Review. Italian.

5. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
J Clin Endocrinol Metab. 1995 Jul;80(7):2118-21.

6. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
Q J Nucl Med. 1995 Jun;39(2):105-10.

7. Association of arginine vasopressin-secreting cell, steroid-secreting cell, adrenal and islet cell antibodies in a patient presenting with central diabetes insipidus, empty sella, subclinical adrenocortical failure and impaired glucose tolerance.
Horm Res. 1995;44(3):142-6.

8. Detection of vasopressin cell antibodies in some patients with autoimmune endocrine diseases without overt diabetes insipidus.
Clin Endocrinol (Oxf). 1994 Feb;40(2):173-7.

9. Relationship between zinc and obesity.
J Med. 1993;24(2-3):177-83.